Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $14.5 million, down from $17.5 million in the same period last year, reflecting a decline due to various factors [11] - The gross profit margin decreased during the quarter, primarily driven by lower 340B contract revenue in the healthcare segment and the expiration of an airtime contract in the e-commerce segment [12][13] - The company ended the quarter with approximately $17.7 million in cash [13] Business Line Data and Key Metrics Changes - In the healthcare segment, there was a decline in prescription volume influenced by changes in provider relationships and patient flow, alongside transitions in pharmacy service agreements [11][12] - E-commerce operations saw an increase in recurring airtime revenue, which grew by 51% due to sustained growth in Internet of Things sales and the impact of the Alphyser acquisition [18] - The healthcare segment is shifting focus towards long-term contracts and new service offerings to improve revenue and margins [15] Market Data and Key Metrics Changes - The current tariff situation has created challenges for the launch of Florida Sunshine products in China, which has been paused, impacting anticipated growth [5][6] - The company is exploring other markets for Florida Sunshine and has seen steady progress in launching OpCo products in China [6][10] Company Strategy and Development Direction - The company is evaluating strategic alternatives, including potential sales or mergers of certain operations and exploring new partnerships and joint ventures to enhance shareholder value [9][10] - There is a commitment to ongoing cost reduction efforts and operational efficiency improvements in the healthcare segment [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by tariffs and the need to adapt strategies to navigate the current market environment [6][21] - The company remains hopeful for a resolution regarding tariffs and is committed to exploring alternative paths for growth [6][22] Other Important Information - The company is actively working to improve its expense structure and has received a substantial performance bonus from a payer, recognizing its quality execution [15] - The company is committed to transparency and sharing progress with investors regarding the steps taken to address industry challenges [23] Q&A Session Summary Question: What is the status of the share buyback? - The company has not repurchased any shares due to legal blackout periods and the need to evaluate cash uses for long-term shareholder value [24][25] Question: Can you comment on Jervis Hall's resignation as director? - The resignation was not due to any disagreement with the company, and while a replacement may be considered, it is not required at this time [26] Question: What is the plan to address the NASDAQ letter and minimum bid requirement? - The company has a six-month period to address the share price and intends to improve financial results and explore strategic alternatives [27] Question: What is the status of ongoing litigation? - The company cannot comment on ongoing litigation [27]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $14.5 million, a decline from $17.5 million in the same period last year, reflecting various operational challenges [10] - The gross profit margin decreased, particularly in the healthcare segment due to lower 340B contract revenue and increased operational costs in the e-commerce segment [12][14] - The company ended the quarter with approximately $17.7 million in cash [12] Business Line Data and Key Metrics Changes - In the healthcare segment, there was a decline in prescription volume and changes in pharmacy service agreements, impacting revenue [10][14] - E-commerce operations saw an increase in recurring airtime revenue, which grew by 51%, but this was offset by a decline in hardware sales [11][16] - The healthcare operations are shifting focus towards long-term contracts and new service offerings to improve margins [14] Market Data and Key Metrics Changes - The current tariff situation has significantly impacted the launch of Florida Sunshine products in China, leading to a pause in those plans [5][19] - The company is exploring other markets for Florida Sunshine and has seen steady progress in launching OpCo products in China [6][19] Company Strategy and Development Direction - The company is evaluating strategic alternatives, including potential sales or mergers of certain operations and exploring new partnerships [9] - There is a commitment to improving operational efficiency and cost structure in the healthcare segment, with a focus on 340B pharmacy service agreements [14] - The company aims to achieve a cash neutral position from operations by 2026, although current conditions may delay this goal [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges due to tariffs and the need to explore alternative markets and products [6][19] - There is optimism regarding the potential for growth in the e-commerce segment, particularly in high-margin recurring revenue streams [16] - The management is committed to transparency and addressing industry challenges to maximize shareholder value [21] Other Important Information - The company received a substantial performance bonus from a payer, recognizing its execution and focus on quality [14] - The company is actively working on cost-saving initiatives and renegotiating vendor contracts to improve its financial position [13] Q&A Session Summary Question: What is the status of the share buyback? - The company has not repurchased any shares due to legal blackout periods and the need to evaluate cash uses for long-term shareholder value [22][23] Question: Can you comment on Jervis Hall's resignation as director? - The resignation was not due to any disagreement with the company, and while a replacement may be considered, it is not required at this time [24] Question: What is the plan to address the NASDAQ letter and minimum bid requirement? - The company has a six-month period to address the share price and intends to improve financial results and explore strategic alternatives [25][26] Question: What is the status of ongoing litigation? - The company cannot comment on ongoing litigation matters [26]